We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

Diversified Trust Co increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 13.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities ...

COPENHAGEN, Denmark, Jan. 10, 2025 /PRNewswire/ -- Novo Holdings, a leading life science investor, today announced that it has invested in a $200M Series A launch financing for Windward Bio.

The newly emerged Swiss biotech’s series A financing was led by OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities, with participation from six other industry investors, according to a ...

The oversubscribed Series A launch financing was co-led by OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities, and joined by SR One, Omega Funds, RTW Investments, Qiming Venture Partners ...

Naveed Siddiqi, Senior Partner, Novo Holdings, said: "Addressing the unmet needs of patients with severe, uncontrolled asthma and COPD, particularly through innovative therapies that reduce the ...

Financing co-led by Novo Holdings A/S and Bpifrance (as part of the InnoBio investment strategy) and joined by leading US and EU investors Invus ...

COPENHAGEN, Denmark , Jan. 6, 2025 /PRNewswire/ -- Novo Holdings today announced its participation in a ?90 million Series A financing for Orbis Medicines. The round was led by New Enterprise ...

Novo Holdings Partner, Morten Graugaard, to lead Orbis as CEO Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties. However, developing these ...